Pfizer Raises Profit Guidance for 2025 as Novo Nordisk Ups Metsera Bid to $10 Billion

Pfizer reported financial results on November 4, 2025, exceeding analysts’ expectations despite a decline in sales. The pharmaceutical company raised its profit guidance for the year, signaling confidence in its operational performance. This announcement comes amid broader industry developments involving major players such as Merck, Novo Nordisk, and Eli Lilly.

Merck disclosed two significant transactions: securing $700 million in funding from Blackstone and spending $150 million to reacquire an asset. Meanwhile, Novo Nordisk increased its bid to $10 billion in the ongoing competition with Pfizer over Metsera’s buyout. Additionally, reports indicate that Eli Lilly and Novo Nordisk are nearing agreements with U.S. regulators regarding pricing for obesity drugs. These updates reflect dynamic shifts within the pharmaceutical sector as companies navigate competitive bids, strategic investments, and regulatory negotiations.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 4, 2025

Related posts:

Biologic Drug Patents Shrink: Average Lifespan Drops to 8.5 Years as Biosimilar Competition Heats Up Study Finds Women Benefit from Fat-Rich Breakfasts While Men Perform Better with Carbohydrate-Heavy Morning Meals Researchers Develop Method to Assess Memory Using Anticipatory Gaze in Non-Verbal Populations Researchers Explore Inoculation Methods to Improve Bacillus Survival in Rice Husk Biochar for Agricultural Use

Author

GOAI